- Home
- IAS vs IMCR Comparison
IAS vs IMCR Comparison
Compare IAS & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IAS
- IMCR
- Stock Information
- Founded
- IAS 2009
- IMCR 2008
- Country
- IAS United States
- IMCR United Kingdom
- Employees
- IAS N/A
- IMCR N/A
- Industry
- IAS Computer Software: Programming Data Processing
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IAS Technology
- IMCR Health Care
- Exchange
- IAS Nasdaq
- IMCR Nasdaq
- Market Cap
- IAS 1.7B
- IMCR 1.4B
- IPO Year
- IAS 2021
- IMCR 2021
- Fundamental
- Price
- IAS $8.31
- IMCR $29.47
- Analyst Decision
- IAS Buy
- IMCR Buy
- Analyst Count
- IAS 10
- IMCR 12
- Target Price
- IAS $15.06
- IMCR $63.00
- AVG Volume (30 Days)
- IAS 1.0M
- IMCR 367.1K
- Earning Date
- IAS 05-08-2025
- IMCR 05-07-2025
- Dividend Yield
- IAS N/A
- IMCR N/A
- EPS Growth
- IAS 475.01
- IMCR N/A
- EPS
- IAS 0.23
- IMCR N/A
- Revenue
- IAS $530,101,000.00
- IMCR $310,202,000.00
- Revenue This Year
- IAS $12.82
- IMCR $18.97
- Revenue Next Year
- IAS $11.81
- IMCR $8.43
- P/E Ratio
- IAS $37.57
- IMCR N/A
- Revenue Growth
- IAS 11.75
- IMCR 24.36
- 52 Week Low
- IAS $7.98
- IMCR $27.19
- 52 Week High
- IAS $13.62
- IMCR $66.00
- Technical
- Relative Strength Index (RSI)
- IAS 27.33
- IMCR 52.19
- Support Level
- IAS $8.87
- IMCR $28.92
- Resistance Level
- IAS $9.13
- IMCR $30.04
- Average True Range (ATR)
- IAS 0.27
- IMCR 1.44
- MACD
- IAS -0.06
- IMCR 0.12
- Stochastic Oscillator
- IAS 17.49
- IMCR 62.58
About IAS Integral Ad Science Holding Corp.
Integral Ad Science Holding Corp is a digital advertising verification company. The cloud-based technology platform of the company delivers independent measurement and verification of digital advertising across all devices, channels, and formats, including desktop, mobile, connected TV, social, display, and video. Geographically, the company derives a majority of its revenue from the Americas region.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.